Chimeric Antigen Receptor (CAR) T-cell Therapy Market to See 44.1% Annual Growth

August 14, 2018

WELLESLEY, Mass., Aug 14, 2018–Exciting developments in the world of immunotherapy are helping to drive incredible growth of the chimeric antigen receptor cell therapy market, according to a report by BCC Research.

The industry is expected to see a compound annual growth rate (CAGR) of 44.1% through 2023, when it is expected to reach $2.9 billion, according to the report Chimeric Antigen Receptor (CAR)-T Cell Therapy: Current Research and Development Status.

Major players in the market include 3S Bio, Ambrx, Batu Biologics, Carsgen Therapeutics, Editas Medicine, Fate Therapeutics, GlaxoSmithKline, F. Hoffman La Roche, Immunocore, Juno Therapeutics, JW Biotechnology, Lokon Pharma, Merck, Novartis, Oxford BioMedica, Partikula, Regen Biopharma, Sangamo Therapeutics, Takara Bio and Ziopharm Oncology.

Research Highlights

  • North America holds 92% of the market, followed by Europe at 7% and the Asia-Pacific region at just 1%.
  • There are two chimeric antigen receptor T-cell therapies currently approved by the U.S. Food and Drug Administration: Kymriah from Novartis and Yescarta from Gilead; Yescarta projects a 2023 value of $2.1 billion, though Kymriah expects a CAGR through the period of 55.9%.
  • Clinical applications of CAR-T-Cell therapy include treatment for tumors of the hematopoietic and lymphoid tissues and solid tumors.

“For years, the foundations of cancer treatment were surgery, chemotherapy, and radiation therapy,” said BCC Research analyst and report author Paul Taylor. “But over the past several years, immunotherapy—therapies that enlist and strengthen the power of a patient’s immune system to attack tumors—has emerged as what many in the cancer community now call the ‘fifth pillar’ of cancer treatment.”

Antigen Loss Relapse and On/Off Tumor Toxicity Among Market Challenges

Although the market has overcome a number of critical obstacles in recent years, several looming challenges remain, notes Taylor. Chief among them are antigen loss relapse, on-target/off-target toxicity resulting from the recognition of healthy tissues by CAR-T cells, and less efficacy in solid tumors due to hostile tumor microenvironments.

Editors/reporters requesting analyst interviews should contact Eric Surber at

Current Research & Developments Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy( BIO162A )
Publish Date: Jul 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.